Clinical Trials

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04886531 2026-03-12

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

53 enrolled

Breast Neoplasms

NCT07053085 2026-02-27

A Study of Surgery and Radiotherapy in People With Breast Cancer

162 enrolled

Breast Neoplasms

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT05376878 2026-02-23

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Phase 4 Recruiting

10 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

20 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

512 enrolled 28 charts

Breast Neoplasms

NCT07416409 2026-02-18

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Completed

80 enrolled

Phase NA Active not recruiting

Breast Neoplasms, Neoplasms

NCT02226276 2026-02-13

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

10 enrolled 8 charts

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

120 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07402473 2026-02-11

EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer

50 enrolled

HER2-positive Early-stage Breast Cancer

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

23 enrolled 10 charts

Breast Neoplasms

NCT06876714 2026-02-04

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Phase 3 Recruiting

1,524 enrolled

Phase 2/3 Not yet recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

Breast Neoplasms

NCT03765983 2026-01-22

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

17 enrolled

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT07340398 2026-01-21

TAYLOR

200 enrolled

HER2-positive Early Breast Cancer

NCT05378464 2026-01-08

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Phase 1 Recruiting

28 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

113 enrolled

Breast Neoplasms

NCT04578106 2026-01-06

ELPIS

5 enrolled 7 charts

Breast Neoplasms

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

48 enrolled

Cancer Related Cognitive Decline

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Breast Neoplasms

NCT03095352 2025-12-22

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

76 enrolled 14 charts

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07136428 2025-12-19

ASCENdANT

42 enrolled

HER2+ Metastatic Breast Cancer

NCT02654119 2025-12-12

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

20 enrolled

Breast Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

13 enrolled

Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06663787 2025-11-28

HER2 CR

Active not recruiting

50 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

188 enrolled

Breast Neoplasms

NCT03571633 2025-11-26

BREASTIMMU02

90 enrolled

Phase 3 Active not recruiting

HER2-positive Breast Cancer

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT01373710 2025-11-24

HIT

Phase 1/2 Completed

34 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

164 enrolled

Breast Neoplasms

NCT04733118 2025-11-20

PHERGAIN-2

393 enrolled

Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04425018 2025-11-18

MARGOT

174 enrolled 19 charts

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

53 enrolled

Metastatic Breast Cancer With a Isolated Brain Progression

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

18 enrolled 8 charts

Breast Neoplasms

NCT04329065 2025-11-06

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

25 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT03738553 2025-10-29

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Active not recruiting

13 enrolled